ERBB2 and breast cancer: The KATE2 study, which compared the efficacy of atezolizumab or placebo plus T-DM1 in HER2-positive advanced breast cancer, failed to show any meaningful clinical benefit on PFS; however, this may also be due to study limitations (e.g., small sample size, unblinded before target number of events reached) (34).